Somatostatin (Sst) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Somatostatin (SST), also known as growth hormone-inhibiting hormone (GHIH), is a 14-amino acid cyclic peptide that functions as a universal inhibitor of hormone secretion and a key neuromodulator in the central nervous system[1]. Encoded by the SST gene, this peptide is produced in multiple forms—somatostatin-14 (predominant in the brain) and somatostatin-28 (predominant in the gut)—and signals through five somatostatin receptors (SSTR1-5) to regulate diverse physiological processes.
Somatostatin adopts a unique cyclic structure essential for its biological activity:
Somatostatin is the primary inhibitor of hormone secretion:
In the CNS, SST functions as inhibitory neuromodulator:
SST-positive cortical interneurons are crucial for:
Somatostatin signals through five G-protein coupled receptors (SSTR1-5), all Gi/o-coupled:
| Receptor | Primary Distribution | Key Functions |
|---|---|---|
| SSTR1 | Cortex, hippocampus | Anti-proliferative |
| SSTR2 | Cortex, pituitary | Cognitive effects |
| SSTR3 | Various | Apoptosis, neuroprotection |
| SSTR4 | Hippocampus | Memory |
| SSTR5 | Pituitary | Hormone regulation |
SST levels are significantly reduced in AD brains, particularly in the hippocampus and cortex[2]. Loss of SST+ interneurons correlates with:
SST replacement or receptor modulation may offer neuroprotective strategies.
SST has anticonvulsant properties:
Somatostatin analogs (octreotide, lanreotide) are first-line treatments for GH-secreting pituitary adenomas.
| Drug | Target | Application | Route |
|---|---|---|---|
| Octreotide | SSTR2, SSTR5 | Acromegaly, NETs | SC/IV |
| Lanreotide | SSTR2, SSTR5 | Acromegaly | SC |
| Pasireotide | SSTR1-5 | Cushing's disease | SC |
| Octreotide LAR | SSTR2, SSTR5 | Acromegaly | IM |
The study of Somatostatin (Sst) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Patel YC. Somatostatin and its receptor family. Frontiers in Neuroendocrinology. 1999;20(3):157-198. PMID:10443881.
Dávila M, González P, Camus M, et al. Somatostatin in Alzheimer's disease: new insights. Neuroscience. 2019;418:1-11. PMID:31454542.
Viollet C, Lepousez G, Loudes C, et al. Somatostatinergic systems in brain. Brain Research. 2008;1225:60-73. PMID:18586026.
Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochimica et Biophysica Acta. 2003;1616(1):1-84. PMID:14507387.
Van Opdenbosch N, Gomar-Nadal E, Batlle M, et al. Somatostatin and neurodegeneration. Cellular and Molecular Neurobiology. 2022;42(5):1465-1478. PMID:33844186.
Epelbaum J, Guillou JL, Gastambide F, et al. Somatostatin, cognition and brain aging. Experimental Gerontology. 2022;161:111755. PMID:35176443.
Somatostatin (SST) acts through five G protein-coupled receptor subtypes (SSTR1-5), with SSTR2 and SSTR5 being the most important for CNS effects. These receptors inhibit adenylate cyclase, reduce cAMP levels, and activate potassium channels, leading to neuronal hyperpolarization. Somatostatin is primarily produced by cortical interneurons, where it plays a critical role in regulating pyramidal neuron activity.
In the hippocampus, somatostatin-expressing interneurons target the perisomatic region of pyramidal cells, providing powerful inhibition that regulates network oscillations and memory consolidation. These neurons are distinct from parvalbumin and cholecystokinin-expressing interneurons, forming a unique inhibitory class.
Alzheimer's Disease: Somatostatin levels are significantly reduced in Alzheimer's disease brains, particularly in the cortex and hippocampus. This deficit may contribute to hippocampal hyperactivity and seizure activity observed in some AD patients. Somatostatin also regulates amyloid-beta production and clearance, linking it directly to AD pathogenesis.
Parkinson's Disease: Somatostatin expression is altered in Parkinson's disease, with effects on motor control and non-motor symptoms. The peptide may modulate dopaminergic neuron survival and function.
Huntington's Disease: Somatostatin interneurons are relatively spared in Huntington's disease compared to other interneuron populations, making them a potential therapeutic target for cell replacement therapies.
Somatostatin analogs (octreotide, lanreotide) are used clinically for neuroendocrine tumors and have been explored for neurodegenerative applications. These compounds may help reduce excitotoxicity and modulate inflammatory responses in the brain.
Research is focused on understanding how somatostatin deficiency contributes to network dysfunction in AD and developing therapies that can restore somatostatin signaling. Novel SSTR subtype-selective agonists are being developed with improved brain penetration.